These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 30305525)

  • 21. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
    Jasiński M; Basak GW; Jedrzejczak WW
    Front Immunol; 2021; 12():632937. PubMed ID: 33717171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of Novel Gene-Modified T-Cell Therapies(CAR-T, TCR-T)].
    Kitano S
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1032-1037. PubMed ID: 38035829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
    Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
    Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.
    Nerreter T; Letschert S; Götz R; Doose S; Danhof S; Einsele H; Sauer M; Hudecek M
    Nat Commun; 2019 Jul; 10(1):3137. PubMed ID: 31316055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes following CAR T cell therapy: what we know so far.
    Cappell KM; Kochenderfer JN
    Nat Rev Clin Oncol; 2023 Jun; 20(6):359-371. PubMed ID: 37055515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric Antigen Receptor T Cells: Immunotherapy for the Treatment of Leukemia, Lymphoma, and Myeloma.
    Rodríguez Gil de Montes AL; Spencer LM
    Mol Cancer Ther; 2023 Nov; 22(11):1261-1269. PubMed ID: 37596239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
    Shah UA; Smith EL
    Cancer J; 2019; 25(3):208-216. PubMed ID: 31135528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [CAR Technology and Its Application in Treatment of Multiple Myeloma--Review].
    Li T; Wang HT; Liu ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):279-84. PubMed ID: 26913437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resisting CAR T-cell Therapy: A Case Study.
    Cancer Discov; 2018 Dec; 8(12):1499-1500. PubMed ID: 30366924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction.
    Lai P; Chen X; Wang Y; Wang J; Zhang Y; Geng S; Li P; Du X; Weng J; Pei D
    J Hematol Oncol; 2022 May; 15(1):68. PubMed ID: 35597971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CARs and other T cell therapies for MM: The clinical experience.
    Danhof S; Hudecek M; Smith EL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):147-157. PubMed ID: 29909915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Identifying and targeting multiple myeloma-specific antigens resulting from post-translational protein modifications by CAR-T cell therapies].
    Hosen N
    Rinsho Ketsueki; 2023; 64(5):427-431. PubMed ID: 37271535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.